Alvespimycin Inhibits Heat Shock Protein 90 and Overcomes Imatinib Resistance in Chronic Myeloid Leukemia Cell Lines

Heat shock protein 90 (HSP90) facilitates folding and stability and prevents the degradation of multiple client proteins. One of these HSP90 clients is BCR-ABL, the oncoprotein characteristic of chronic myeloid leukemia (CML) and the target of tyrosine kinase inhibitors, such as imatinib. Alvespimyc...

Descripción completa

Detalles Bibliográficos
Autores principales: Alves, Raquel, Santos, Diogo, Jorge, Joana, Gonçalves, Ana Cristina, Catarino, Steve, Girão, Henrique, Melo, Joana Barbosa, Sarmento-Ribeiro, Ana Bela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9920317/
https://www.ncbi.nlm.nih.gov/pubmed/36770876
http://dx.doi.org/10.3390/molecules28031210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9920317/
https://www.ncbi.nlm.nih.gov/pubmed/36770876
http://dx.doi.org/10.3390/molecules28031210

Ejemplares similares